Results 91 to 100 of about 5,080 (193)

Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation [PDF]

Background: Acetylcholinesterase inhibitors (AChEIs) provide symptomatic relief in Alzheimer’s disease (AD), whereas lecanemab may modify disease progression; however, real-world evidence on its safety and clinical impact remains limited. Therefore, this
Tseng, Ping-Tao, Hsu, Tien-Wei, Lin, Yu-Hsuan, Liang, Chih-Sung, Stubbs, Brendon, Thompson, Trevor, Fang, Yi-Ya, Lee, Chuo-Yu, Hsu, Chih-Wei, Kao, Yu-Chen, Yang, Fu-Chi, Carvalho, Andre F.   +11 more
core   +1 more source

Steroid-responsive inflammatory leptomeningeal encephalitis temporally associated with lecanemab therapy: A case report

Journal of Alzheimer's Disease Reports
Lecanemab is an anti–amyloid-β monoclonal antibody used for the treatment of early Alzheimer's disease. Herein, we report a 46-year-old woman who developed headache, fever, disorientation, and impaired consciousness 10 months after starting lecanemab ...
Yuichiro Tagane, Masahiro Nakamori, Marina Ishida, Saya Tsuchigauchi, Takamichi Sugimoto, Yu Yamazaki, Hirofumi Maruyama   +6 more
doaj   +1 more source

Does the Current Evidence for Lecanemab Mechanism Support a Rationale for Continued Lecanemab Dosing?

Alzheimer's & Dementia
AbstractAlzheimer’s disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that ...
Selkoe, Dennis J., Dhadda, Shobha, Irizarry, Michael C., Kramer, Lynn D   +3 more
openaire   +1 more source

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab

Frontiers in Pharmacology
BackgroundLecanemab is a humanized murine IgG1 antibody. Recent Phase 3 clinical trials have demonstrated its ability to reduce brain amyloid-β (Aβ) load and slow cognitive decline in patients with early Alzheimer’s disease (AD).
Linlin Yan, Linhai Zhang, Zucai Xu, Zhong Luo   +3 more
doaj   +1 more source

Simulation of long‐term lecanemab treatment effect on Alzheimer's disease progression

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Anti‐amyloid therapies such as lecanemab have demonstrated statistically significant slowing of decline on the Clinical Dementia Rating‐Sum of Boxes (CDR‐SB) in patients with early Alzheimer's disease (AD) in pivotal trials.
Troy Williams, Se Ryeong Jang, Krista L. Lanctôt, Ashley Kang, Lisa Bloudek, Guoqiao Wang   +5 more
doaj   +1 more source

Advance in Lecanemab therapy for Alzheimer's disease

Chinese Journal of Contemporary Neurology and Neurosurgery
Deposition of amyloid β-protein (Aβ) in the brain is a key pathogenesis and early change in Alzheimer's disease (AD). Clearing Aβ through anti-Aβ monoclonal antibody drugs is an important strategy for disease-modifying thrapy (DMT).
QIANG Qi-qi, LIU Pei-jie, CUI Si-meng, QU Qiu-min   +3 more
doaj   +1 more source

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Monoclonal antibodies (mAbs) for Alzheimer's disease (AD) represent major therapeutic advances, but their economic value is uncertain.
Tuyet Thao Nguyen, Bozhidar T. Chakalov, Megan Van Noord, Charles DeCarli, Jeffrey S. Hoch   +4 more
doaj   +1 more source

Combined 64-channel EEG and PET evaluation of lecanemab efficacy: Two case reports

Journal of Alzheimer's Disease Reports
Lecanemab, an anti-amyloid-β (Aβ) monoclonal antibody, has shown potential in slowing Alzheimer's disease (AD) progression. We report divergent responses in two AD patients with similar backgrounds following lecanemab treatment. Subject 1 showed worsened
Xichun Wang, Yumei Liu, Shuhan Fan, Hong Zhao, Chang Sun, Lu Liu, Xiangcheng Wang, Liangyu Zou   +7 more
doaj   +1 more source

THERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB

Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder and the leading cause of dementia worldwide, with prevalence increasing due to population aging.
Natasza Kurys, Szymon Litke, Weronika Piekarska, Katarzyna Gołacka, Gabriela Majchrowicz, Mikołaj Jońca   +5 more
core   +1 more source

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer’s disease and a literature review

BMC Neurology
Objective To investigate the imaging characteristics and management strategies of amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease (AD) patients treated with lecanemab.
Yingte Wang, Qun Yu, Bin Chen, Jing Zhou, Zhiming Li, Wang Liao, Jun Liu, Airong Yang   +7 more
doaj   +1 more source